Flurbiprofen in the treatment of acute gout: A comparison with indomethacin

https://doi.org/10.1016/0002-9343(86)90131-2Get rights and content

Abstract

The relative efficacy and safety of flurbiprofen (Ansaid, Upjohn) and indomethacin were compared in 29 patients with monoarticular gouty arthritis of less than 48 hours' duration. A loading dose of 400 mg of flurbiprofen or 200 mg of indomethacin was administered for 24 hours, followed by 200 mg of flurbiprofen per day or 100 mg of indomethacin per day for a maximum of five days. Based on global assessment of improvement, at least 50 percent of patients in both treatment groups showed improvement within 24 hours. There were statistically significant improvements in pain, swelling, erythema, and skin temperature in both groups of patients within 48 hours of treatment. By 72 hours, the proportion of patients with improvement in the flurbiprofen group was equal to or greater than the proportion in the indomethacin group for all clinical efficacy parameters. At the end of treatment, eight of 15 patients in the indomethacin group and five of 14 patients in the flurbiprofen group were asymptomatic. There were no statistically significant differences between indomethacin and flurbiprofen in the percentage of asymptomatic patients at the end of treatment. Side effects were mild in both groups. No clinically significant between-treatment differences were noted in vital signs or in the results of laboratory assays.

References (6)

There are more references available in the full text version of this article.

Cited by (40)

  • Influence of the spacer on the photoreactivity of flurbiprofen-tyrosine dyads

    2016, Journal of Photochemistry and Photobiology A: Chemistry
    Citation Excerpt :

    For instance, the presence of a Tyr residue influences the esterase activity of bovine serum albumin (BSA) [18]. Flurbiprofen (FBP, Scheme 1) is a nonsteroidal anti-inflammatory drug (NSAID) prescribed for treatment of osteoarthritis, rheumatoid arthritis, tendinitis, bursitis, sunburns and prevention of migraine headache [19–24]. Although it is prescribed as a racemic mixture, its pharmacological effect is attributed to the (S)- enantiomer [25,26].

  • Management of gout in the older adult

    2011, American Journal Geriatric Pharmacotherapy
    Citation Excerpt :

    Rather, the most important determinant appears to be the timing of initiation of the NSAID, as opposed to which specific agent. Table II summarizes clinical trial information regarding NSAID use in the treatment of acute gout.19–23,25,26 In an elderly patient with gout, potential adverse effects associated with NSAIDs need to be seriously considered when tailoring therapy.

  • Clinical Trials in Crystal Arthropathy

    2006, Rheumatic Disease Clinics of North America
View all citing articles on Scopus

The work presented was based on the administration of Ansaid tablets, a registered trademark of The Upjohn Company.

View full text